Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Raymond James a virtual conference » 04:55
06/18/20
06/18
04:55
06/18/20
04:55
XNCR

Xencor

$29.85 /

-0.32 (-1.06%)

, BBIO

BridgeBio

$31.66 /

-0.07 (-0.22%)

, MGTA

Magenta Therapeutics

$9.39 /

+0.175 (+1.90%)

, OCUL

Ocular Therapeutix

$8.68 /

-0.15 (-1.70%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

XNCR Xencor
$29.85 /

-0.32 (-1.06%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

XNCR Xencor
$29.85 /

-0.32 (-1.06%)

OCUL Ocular Therapeutix
$8.68 /

-0.15 (-1.70%)

MGTA Magenta Therapeutics
$9.39 /

+0.175 (+1.90%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

BBIO BridgeBio
$31.66 /

-0.07 (-0.22%)

Hot Stocks
Abeona Therapeutics appoints George Migausky, Paul Mann to board of directors » 07:37
06/17/20
06/17
07:37
06/17/20
07:37
ABEO

Abeona Therapeutics

$3.13 /

+0.01 (+0.32%)

, PTE

PolarityTE

$1.44 /

+0.015 (+1.06%)

, OCUL

Ocular Therapeutix

$8.83 /

+0.57 (+6.90%)

Abeona Therapeutics…

Abeona Therapeutics (ABEO) announced Board of Director appointments that strengthen and expand the Company's leadership. George Migausky and Paul Mann were appointed as independent directors, effective June 17, 2020. In addition to their Board service, Mr. Migausky will serve as Chairman of the Company's Audit Committee and Mr. Mann will serve as a member of the Audit Committee. Most recently, Migausky served as interim CFO of Ocular Therapeutix (OCUL) and Mann served as CFO at PolarityTE (PTE).

ShowHide Related Items >><<
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

Conference/Events
Raymond James a virtual conference » 04:55
06/17/20
06/17
04:55
06/17/20
04:55
XNCR

Xencor

$30.17 /

+0.09 (+0.30%)

, BBIO

BridgeBio

$31.73 /

+0.62 (+1.99%)

, MGTA

Magenta Therapeutics

$9.22 /

-0.005 (-0.05%)

, OCUL

Ocular Therapeutix

$8.83 /

+0.57 (+6.90%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

XNCR Xencor
$30.17 /

+0.09 (+0.30%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

XNCR Xencor
$30.17 /

+0.09 (+0.30%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

MGTA Magenta Therapeutics
$9.22 /

-0.005 (-0.05%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

BBIO BridgeBio
$31.73 /

+0.62 (+1.99%)

Conference/Events
Raymond James a virtual conference » 04:55
06/16/20
06/16
04:55
06/16/20
04:55
XNCR

Xencor

$30.08 /

+1.64 (+5.77%)

, BBIO

BridgeBio

$31.11 /

+2.4 (+8.36%)

, MGTA

Magenta Therapeutics

$9.22 /

+0.14 (+1.54%)

, OCUL

Ocular Therapeutix

$8.26 /

+0.8 (+10.72%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

XNCR Xencor
$30.08 /

+1.64 (+5.77%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

XNCR Xencor
$30.08 /

+1.64 (+5.77%)

OCUL Ocular Therapeutix
$8.26 /

+0.8 (+10.72%)

MGTA Magenta Therapeutics
$9.22 /

+0.14 (+1.54%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

BBIO BridgeBio
$31.11 /

+2.4 (+8.36%)

Conference/Events
Raymond James a virtual conference » 09:10
06/15/20
06/15
09:10
06/15/20
09:10
XNCR

Xencor

$28.44 /

-0.77 (-2.64%)

, BBIO

BridgeBio

$28.71 /

+0.72 (+2.57%)

, MGTA

Magenta Therapeutics

$9.08 /

-0.05 (-0.55%)

, OCUL

Ocular Therapeutix

$7.46 /

+0.37 (+5.22%)

Human Health Innovation…

Human Health Innovation Virtual Conference will be held on June 15-18.

ShowHide Related Items >><<
XNCR Xencor
$28.44 /

-0.77 (-2.64%)

OCUL Ocular Therapeutix
$7.46 /

+0.37 (+5.22%)

MGTA Magenta Therapeutics
$9.08 /

-0.05 (-0.55%)

BBIO BridgeBio
$28.71 /

+0.72 (+2.57%)

XNCR Xencor
$28.44 /

-0.77 (-2.64%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
BBIO BridgeBio
$28.71 /

+0.72 (+2.57%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
MGTA Magenta Therapeutics
$9.08 /

-0.05 (-0.55%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
OCUL Ocular Therapeutix
$7.46 /

+0.37 (+5.22%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
XNCR Xencor
$28.44 /

-0.77 (-2.64%)

OCUL Ocular Therapeutix
$7.46 /

+0.37 (+5.22%)

MGTA Magenta Therapeutics
$9.08 /

-0.05 (-0.55%)

BBIO BridgeBio
$28.71 /

+0.72 (+2.57%)

XNCR Xencor
$28.44 /

-0.77 (-2.64%)

OCUL Ocular Therapeutix
$7.46 /

+0.37 (+5.22%)

MGTA Magenta Therapeutics
$9.08 /

-0.05 (-0.55%)

BBIO BridgeBio
$28.71 /

+0.72 (+2.57%)

BBIO BridgeBio
$28.71 /

+0.72 (+2.57%)

Over a month ago
Syndicate
Ocular Therapeutix 8.182M share Spot Secondary priced at $5.50 » 07:33
05/20/20
05/20
07:33
05/20/20
07:33
OCUL

Ocular Therapeutix

$6.45 /

-0.31 (-4.59%)

The deal size was…

The deal size was increased to $45M in common stock, up from $35M. Jefferies and Piper Sandler & Co. are acting as joint book running managers for the offering.

ShowHide Related Items >><<
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

  • 20
    May
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

On The Fly
Fly Intel: After-Hours Movers » 18:42
05/19/20
05/19
18:42
05/19/20
18:42
KRNT

Kornit Digital

$35.70 /

+0.11 (+0.31%)

, CSV

Carriage Services

$15.94 /

+0.705 (+4.63%)

, EIGR

Eiger BioPharmaceuticals

$12.28 /

-0.42 (-3.31%)

, IIN

IntriCon

$13.12 /

+1.32 (+11.19%)

, URBN

Urban Outfitters

$17.92 /

-0.875 (-4.66%)

, RRR

Red Rock Resorts

$10.77 /

+0.71 (+7.06%)

, MRNA

Moderna

$71.61 /

-8.39 (-10.49%)

, ALRM

Alarm.com

$49.92 /

+0.25 (+0.50%)

, VNRX

VolitionRx

$3.15 /

-0.35 (-10.00%)

, OCUL

Ocular Therapeutix

$6.45 /

-0.31 (-4.59%)

, BDX

Becton Dickinson

$262.94 /

-1.99 (-0.75%)

, CSGP

CoStar Group

$675.74 /

+19.63 (+2.99%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VNRX VolitionRx
$3.15 /

-0.35 (-10.00%)

URBN Urban Outfitters
$17.92 /

-0.875 (-4.66%)

RRR Red Rock Resorts
$10.77 /

+0.71 (+7.06%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

MRNA Moderna
$71.61 /

-8.39 (-10.49%)

KRNT Kornit Digital
$35.70 /

+0.11 (+0.31%)

IIN IntriCon
$13.12 /

+1.32 (+11.19%)

EIGR Eiger BioPharmaceuticals
$12.28 /

-0.42 (-3.31%)

CSV Carriage Services
$15.94 /

+0.705 (+4.63%)

CSGP CoStar Group
$675.74 /

+19.63 (+2.99%)

BDX Becton Dickinson
$262.94 /

-1.99 (-0.75%)

ALRM Alarm.com
$49.92 /

+0.25 (+0.50%)

KRNT Kornit Digital
$35.70 /

+0.11 (+0.31%)

04/06/20 Craig-Hallum
Kornit Digital downgraded to Hold from Buy at Craig-Hallum
04/06/20 Craig-Hallum
Kornit Digital downgraded to Hold from Buy at Craig-Hallum
03/18/20 Needham
Kornit Digital price target lowered to $33 from $45 at Needham
02/28/20 Stifel
Kornit Digital selloff brings attractive entry point, says Stifel
CSV Carriage Services
$15.94 /

+0.705 (+4.63%)

04/08/20 Barrington
Carriage Services recent weakness a buying opportunity, says Barrington
02/21/20 Barrington
Carriage Services to continue with improving organic growth, says Barrington
01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
12/03/19 Barrington
Carriage Services price target raised to $35 from $30 at Barrington
EIGR Eiger BioPharmaceuticals
$12.28 /

-0.42 (-3.31%)

06/26/19 Citi
Eiger BioPharmaceuticals initiated with a Buy at Citi
06/18/19 Jefferies
Eiger breakthrough designation a surprise, says Jefferies
IIN IntriCon
$13.12 /

+1.32 (+11.19%)

01/08/20 B. Riley FBR
B. Riley FBR highlights six Specialty Pharma stocks for 2020
09/20/19
IntriCon initiated with a Buy at Dougherty
URBN Urban Outfitters
$17.92 /

-0.875 (-4.66%)

05/18/20 Wedbush
Urban Outfitters price target lowered to $18 from $25 at Wedbush
05/15/20 MKM Partners
Urban Outfitters price target lowered to $15 from $23 at MKM Partners
05/14/20 Barclays
Urban Outfitters price target lowered to $16 from $25 at Barclays
04/20/20 Loop Capital
Urban Outfitters price target lowered to $18 from $23 at Loop Capital
RRR Red Rock Resorts
$10.77 /

+0.71 (+7.06%)

02/05/20 Deutsche Bank
Red Rock Resorts price target raised to $31 from $25 at Deutsche Bank
02/05/20 Nomura Instinet
Red Rock Resorts price target raised to $30 from $26 at Nomura Instinet
02/04/20
Fly Intel: Top five analyst upgrades
02/04/20 SunTrust
Red Rock Resorts upgraded to Buy from Hold at SunTrust
MRNA Moderna
$71.61 /

-8.39 (-10.49%)

05/19/20 Piper Sandler
Piper trims Moderna target to $100 on capital raise dilution
05/19/20 BMO Capital
Moderna price target raised to $112 from $83 at BMO Capital
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/18/20 Roth Capital
Moderna taking COVID-19 vaccine 'by the horns,' says Roth Capital
ALRM Alarm.com
$49.92 /

+0.25 (+0.50%)

05/06/20 Raymond James
Alarm.com price target lowered to $55 from $65 at Raymond James
01/27/20 Imperial Capital
Alarm.com upgraded to Outperform from In-Line at Imperial Capital
12/01/19 First Analysis
First Analysis reiterates Strong Buy on Alarm.com after meeting management
10/21/19 First Analysis
Alarm.com upgraded to Strong Buy from Outperform at First Analysis
VNRX VolitionRx
$3.15 /

-0.35 (-10.00%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
BDX Becton Dickinson
$262.94 /

-1.99 (-0.75%)

05/14/20 Piper Sandler
Becton Dickinson price target raised to $296 from $286 at Piper Sandler
04/08/20 Wells Fargo
Becton Dickinson price target lowered to $270 from $279 at Wells Fargo
03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
CSGP CoStar Group
$675.74 /

+19.63 (+2.99%)

04/29/20 SunTrust
CoStar Group price target lowered to $695 from $790 at SunTrust
04/29/20 Wells Fargo
CoStar Group price target lowered to $755 from $800 at Wells Fargo
04/23/20 B. Riley FBR
CoStar Group price target lowered to $730 from $780 at B. Riley FBR
02/26/20 SunTrust
CoStar Group price target raised to $790 from $650 at SunTrust
URBN Urban Outfitters
$17.92 /

-0.875 (-4.66%)

RRR Red Rock Resorts
$10.77 /

+0.71 (+7.06%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

MRNA Moderna
$71.61 /

-8.39 (-10.49%)

KRNT Kornit Digital
$35.70 /

+0.11 (+0.31%)

IIN IntriCon
$13.12 /

+1.32 (+11.19%)

EIGR Eiger BioPharmaceuticals
$12.28 /

-0.42 (-3.31%)

CSV Carriage Services
$15.94 /

+0.705 (+4.63%)

CSGP CoStar Group
$675.74 /

+19.63 (+2.99%)

BDX Becton Dickinson
$262.94 /

-1.99 (-0.75%)

ALRM Alarm.com
$49.92 /

+0.25 (+0.50%)

  • 20
    May
  • 20
    May
  • 20
    May
  • 21
    May
  • 21
    May
  • 19
    May
MRNA Moderna
$71.61 /

-8.39 (-10.49%)

BDX Becton Dickinson
$262.94 /

-1.99 (-0.75%)

URBN Urban Outfitters
$17.92 /

-0.875 (-4.66%)

RRR Red Rock Resorts
$10.77 /

+0.71 (+7.06%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

MRNA Moderna
$71.61 /

-8.39 (-10.49%)

BDX Becton Dickinson
$262.94 /

-1.99 (-0.75%)

VNRX VolitionRx
$3.15 /

-0.35 (-10.00%)

URBN Urban Outfitters
$17.92 /

-0.875 (-4.66%)

RRR Red Rock Resorts
$10.77 /

+0.71 (+7.06%)

MRNA Moderna
$71.61 /

-8.39 (-10.49%)

Syndicate
Ocular Therapeutix $35M spot secondary re-offered at $5.50 per share  18:01
05/19/20
05/19
18:01
05/19/20
18:01
OCUL

Ocular Therapeutix

$6.45 /

-0.31 (-4.59%)

 
ShowHide Related Items >><<
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

  • 20
    May
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

Syndicate
Ocular Therapeutix files to sell common stock, no amount given » 16:44
05/19/20
05/19
16:44
05/19/20
16:44
OCUL

Ocular Therapeutix

$6.45 /

-0.31 (-4.59%)

Jefferies and Piper…

Jefferies and Piper Sandler & Co. are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

OCUL Ocular Therapeutix
$6.45 /

-0.31 (-4.59%)

Recommendations
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler » 07:45
05/15/20
05/15
07:45
05/15/20
07:45
OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

Ocular Therapeutix (OCUL)…

Ocular Therapeutix (OCUL) yesterday "quietly" provided an update for OTX-TKI in a regulatory filing related to an amendment around the Regeneron (REGN) collaboration, Piper Sandler analyst Joseph Catanzaro tells investors in a research note. Specifically, the first two patients in the high dose cohort have now shown clinically meaningful reductions in intraretinal and/or subretinal fluid out to six months, says the analyst. Further, he believes the safety profile remains favorable with no serious ocular adverse events. Catanzaro continues to be encouraged by these early data and signs of clinically meaningful durability. The analyst keeps an Overweight rating on Ocular Therapeutix with an $11 price target.

ShowHide Related Items >><<
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.